Micardis HCT 40-12.5 MG tablet UD 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F9BQR
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,807
Award facts
- Contract value 100% obligated
- $1,807.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $1,807.12 to AmerisourceBergen Drug Corp for the supply of Micardis HCT 40-12.5 mg tablets (30-count unit dose packaging) with a firm fixed price and completion deadline of December 18, 2025. This non-set-aside competitive award was issued to AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, where the pharmaceutical products will be supplied from. The delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 through December 2026.
AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor and healthcare solutions provider for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. The company's extensive federal contract portfolio demonstrates its capability to supply a comprehensive range of pharmaceutical products across multiple therapeutic domains, from specialty medications and brand-name drugs to generic pharmaceuticals and medical devices. This particular delivery order for Micardis HCT, an antihypertensive combination medication, reflects the routine pharmaceutical supply requirements fulfilled under the company's prime vendor agreement with DLA, which enables flexible sourcing of critical medical commodities to support Defense Health Agency operations and other federal healthcare systems globally.
Quick answers
Who was awarded contract SPE2DR26F9BQR?
SPE2DR26F9BQR was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 17, 2025.
How much is contract SPE2DR26F9BQR worth?
The government has obligated $1,807 on SPE2DR26F9BQR.
Is contract SPE2DR26F9BQR an order under another contract?
Yes. SPE2DR26F9BQR is a delivery order under SPE2DR25D1017, an indefinite delivery contract.
Was contract SPE2DR26F9BQR competed?
The extent of competition for SPE2DR26F9BQR was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award